Key Highlights

  • Genmab furnished its current Articles of Association, dated September 24, 2026, and attached them as Exhibit 3.1.
  • The document is incorporated by reference into six of the company's Form S-8 registration statements.
  • Share capital is stated as DKK 62,405,855, divided into shares of DKK 1 each, each carrying one vote.
  • The board holds authorizations until March 12, 2029 to increase capital by up to DKK 6,600,000 and issue convertible debt.

Genmab A/S (NASDAQ:GMAB) furnished a Form 6-K on September 29, 2026 whose sole purpose is to place its current Articles of Association on the public record. The document, dated September 24, 2026, is attached as Exhibit 3.1, and the cover report states that it is incorporated by reference into six of the company's Form S-8 registration statements.

The filing was signed on September 29, 2026 by Anthony Pagano, Executive Vice President and Chief Financial Officer.

Why the Articles Were Furnished

Form S-8 registration statements are used by companies to register shares offered under employee benefit and Equity plans. When such a statement is on file, the company's later reports can be incorporated into it by reference, which keeps the disclosure available to plan participants current. The 6-K lists the six S-8 file numbers affected: 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505. By furnishing the updated articles in this way, Genmab makes the current governing document part of each of those registrations.

The cover report does not say what changed from the previous version of the articles or which provision prompted the update. It identifies the document by its date and attaches the full text, so earlier versions would need to be compared separately.

What the Articles of Association Say

The exhibit gives Genmab's Share Capital as DKK 62,405,855, divided into shares of DKK 1 each. It describes the company's objects as medical research, production and sale of such products and related business, and it states that the group language is English. The financial year runs from January 1 to December 31, and annual reports are prepared in English, with an optional Danish version, following Danish rules and IFRS and possibly US GAAP.

The articles contain standing authorizations for the board of directors. One allows the board, until March 12, 2029, to increase the share capital by up to DKK 6,600,000, with or without pre-emption rights, at Market Price or higher. Another allows convertible Debt instruments of up to DKK 3,000,000 until the same date, and the articles provide that the two authorizations together cannot exceed DKK 6,600,000 in nominal increase.

The articles also list authorizations to issue warrants to employees, other than executive management, of DKK 750,000 nominal value each, dated March 13, 2024 and March 12, 2025, with expiry dates of March 12, 2029 and March 11, 2030. An earlier Warrant authorization from April 13, 2021 is shown with an expiry of April 12, 2026.

On governance, the articles provide for a board of three to nine members elected by the general meeting for one-year terms, with the board choosing its own chairman. Annual general meetings are held within four months of the financial year end in Copenhagen or the greater Copenhagen area, with notice of three to five weeks, and each share carries one vote. Ordinary resolutions need a simple majority, while amendments to the articles need a two-thirds majority. Virtual meetings are permitted at the board's discretion.

Genmab's Share Capital Authorizations Stay in Place Through 2029

The filing itself sets no deadline or follow-up event. The practical points to watch are Genmab's future filings, in which the share capital figure in the articles could change if new shares are issued under the authorizations, and any later versions of the articles, which would again be furnished in a similar way. The board authorizations described in the exhibit run to dates in 2029 and 2030, so they remain in place well beyond the current reporting period unless changed by shareholders.